Drugs of Abuse Testing Market: Stringent Norms at Workplaces to Drive Demand

The growing illicit consumption of drugs across the globe has led to the augmentation of the global drugs of abuse testing market. The negative impact caused by drug abuse on the abusers as well as those around them have compelled non-profit organizations and governments to take a stern action against illicit drug abuse. This has created a high demand for on-the-spot testing so as to carry out random checks and reduce the incidence of mishaps. Transparency Market Research in its latest report states that the global drugs of abuse testing market will be worth US$6.4 bn by the end of 2024.

Given below are three important questions answered by a TMR analyst on the global drugs of abuse testing market:

Q. What are the key factors boosting the growth of the drugs of abuse testing market?

The growing presence of clinical laboratories is one of the key factors fueling the demand for drugs of abuse testing products. Stringent norms at workplaces that require employees to be free from drug abuse in any form will also drive the demand for these products. The staggering increase in the number of deaths on account of abuse of prescription drugs is creating a heightened need for hospitals and labs to carry out tests that detect drug abuse and this will boost the demand for drugs of abuse testing products. 


Q. Which region is anticipated to be a key market for drugs of abuse testing market?

North America is foreseen to be a leading market for drugs of abuse testing and is likely to expand at a 5.7% CAGR between 2016 and 2024. The growing awareness among people as well as the increasing efforts to keep work environment safe from illicit activities shall drive the market in North America, with the U.S. being the key region with high demand for drug abuse testing screenings.  Europe is also estimated to be a key market in the years to come for drugs of abuse testing on account of the staggering high incidences of abuse of prescription drugs.

Q. What are the recent developments by key players in the drugs of abuse testing market?

Alere Inc. in July 2017 announced its latest product, which is a point-of-care Alere iCup® Rx Drug Screen. This is a urine test that can detect five of the most commonly misused prescription drugs, viz oxycodone, benzodiazepines, methadone, buprenorphine, and opiates. The test facilitates early detection of abuse and thus ensures patient compliance with legitimately prescribed therapies. This test streamlines testing and monitoring of patients in a medical setting as well as in addiction management facilities. The product features a self-contained collection cup plus test device. It offers auto-activated results within five minutes of no tipping of the cup. It also has a specimen validity test (SVT) which monitors specimen tampering.

Another key player, Siemens Healthineers has developed the V-Twin® System which is fast and easy to use, and processes a higher number of tests in low cost. It makes use of its own backup system and is thus, more reliable. It features twin-unite design and enables a broad menu of drugs of abuse. The product enables validity testing, therapeutic drug testing assays, and toxicology. 

0 comments:

Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports